AUTL
Autolus Therapeutics plc
AUTL
Autolus Therapeutics plc
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gross margin of approximately 35% year-to-date FY 2026 sales guidance increased to $140 – $150 million
Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, especially with obe-cel in oncology and autoimmune diseases. Obe-cel's expansion into lupus nephritis an